Abstract
Thymidine phosphorylase (TP) is an enzyme that acts as a proangiogenic factor. Overexpression of the enzyme was observed in various solid tumors and several chronic inflammatory diseases, where it was correlated with level of angiogenesis and elevated progression of the disease. TP inhibitors are compounds designed to interfere with the processes connected with catalytic function of this enzyme including TP-mediated angiogenesis and the degradation of important antiviral and anticancer drugs. This chapter comprehensively reviews the hitherto known TP inhibitors with further insight into their potential applications in the clinical practices.
Keywords: Thymidine phosphorylase, angiogenesis, platelet-derived endothelial cell growth factor, gliostatin, cancer chemotherapy, thymidine phosphorylase inhibitors.
Related Journals
Current Drug Delivery
Current Bioactive Compounds
Current Drug Safety
Reviews on Recent Clinical Trials
Drug Delivery Letters
Recent Advances in Drug Delivery and Formulation
Recent Advances in Anti-Infective Drug Discovery
Drug Metabolism and Bioanalysis Letters
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Drug Targets - Inflammation & Allergy
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms
Current Technologies To Increase The Transdermal Delivery Of Drugs
Current Technologies To Increase The Transdermal Delivery Of Drugs
Drug Design and Discovery in Alzheimer's Disease
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Anti-Cancer Drug Discovery